NCT04781725 - INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 25, 2021

Primary Completion Date

March 1, 2022

Study Completion Date

March 1, 2023

Conditions

Breast Cancer

Interventions

DRUG

INT230-6

INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also known as SHAO-FA or SHAO as a sodium salt at 10mg/mL).

OTHER

Saline injection

Standard 0.9 % NaCl Normal Saline

Trial Locations (1)

K1Y 4E9

RECRUITING

The Ottawa Hospital Research Institute and Cancer Center, Ottawa